Clinical Trials
9
Active:4
Completed:0
Trial Phases
2 Phases
Phase 1:7
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (77.8%)Phase 2
2 (22.2%)TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
Terminated
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 27
- Registration Number
- NCT05980598
- Locations
- 🇨🇳
Ascendis Investigational Site, Taoyuan, Taiwan
🇺🇸Ascendis Pharma Investigational Site, Canton, Ohio, United States
🇪🇸Ascendis Investigational Site II, Madrid, Spain
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma2L+ Cervical CancerNeoadjuvant MelanomaNeoadjuvant Non-Small Cell Lung CancerPost Anti-PD-(L)1 Non-Small Cell Lung CancerPost Anti-PD-(L)1 Small Cell Lung Cancer
- Interventions
- Drug: Chemotherapy drugProcedure: Surgery
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 345
- Registration Number
- NCT05081609
- Locations
- 🇨🇳
Ascendis Pharma Investigational Site, Taipei, Taiwan
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced Solid TumorAdvanced Solid TumorMetastatic Solid TumorHPV-associated CancersNeoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)Head and Neck Squamous Cell Carcinoma HNSCCNeoadjuvant Melanoma
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 188
- Registration Number
- NCT04799054
- Locations
- 🇦🇺
Ascendis Pharma Investigational Site, Frankston, Victoria, Australia
🇨🇳Ascendis Investigational Site, Taipei City, Taiwan
News
No news found